Methylene Blue vs MK-677
Well Studied vs Well Studied
avoid Mechanism-based · 64% Both Methylene Blue and MK-677 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Methylene Blue MK-677
Weight 319.85 Da 624.77 Da
Half-life ~5-6 hours ~24 hours
Type Phenothiazine dye (C16H18ClN3S) Non-peptide ghrelin receptor agonist
Key Benefits
Methylene Blue
01 Enhances mitochondrial respiration and ATP production by acting as an alternative electron carrier
02 Reduces mitochondrial reactive oxygen species generation
03 Supports memory consolidation and cognitive performance at low doses
04 Neuroprotective effects demonstrated in models of Alzheimer's, Parkinson's, and traumatic brain injury
05 Improves mitochondrial function in aging cells and tissues
06 FDA-approved treatment for acquired methemoglobinemia
07 Anti-inflammatory and antimicrobial properties
MK-677
01 97% increase in 24-hour growth hormone secretion
02 40-72% elevation in IGF-1 levels
03 Enhanced sleep quality with improved REM patterns
04 Preferential lean tissue gains of 1.1-2.7kg over 8-12 months
05 15% basal metabolic rate increase within 2 weeks
06 Oral administration (no injections required)
Side Effects
Methylene Blue
Blue or blue-green discoloration of urine (expected and harmless)
Blue-green staining of the tongue and mouth with liquid formulations
Mild nausea or stomach discomfort, especially at higher doses
Blue discoloration of stool
Mild headache during initial use
MK-677
Appetite stimulation (>50% of users)
Water retention (30-40%)
Lethargy (20-30%)
Fasting glucose elevation (5-15mg/dL)
Note on testosterone suppression: at doses up to 20 mg daily, MK-677 is unlikely to cause significant testosterone suppression on its own. Above 20 mg daily, the likelihood of suppression and other side effects (insulin resistance, water retention, lethargy) increases. The case report documenting 85.7% testosterone suppression involved co-administration with LGD-4033, a SARM known to be profoundly suppressive, making the SARM the likely primary driver of that suppression.
Contraindications
Concurrent use of SSRIs, SNRIs, or MAO inhibitors (serotonin syndrome risk)
Glucose-6-phosphate dehydrogenase (G6PD) deficiency (risk of severe hemolytic anemia)
Renal insufficiency (methylene blue is primarily renally excreted)
Known hypersensitivity to methylene blue or phenothiazine compounds
Pregnancy and breastfeeding (insufficient safety data)
Heart disease or congestive heart failure
Diabetes or pre-diabetes
Active cancer
Severe cardiovascular disease
Pregnancy or breastfeeding
Research Evidence
Methylene Blue MK-677
Status Well Studied Well Studied
References 5 studies 7 studies
Latest 2017 July 2024
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.